Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.
A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Evaluate the Efficacy And Safety of UK-432,097 Dry Powder For Inhalation In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease.
Sponsor: Pfizer
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Pfizer
Other Pulmonary Disease, Chronic Obstructive trials with similar outcome
A PHASE2 clinical study on Pulmonary Disease, Chronic Obstructive, this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Almelo, Netherlands , Bydgoszcz, Poland , Calgary, Canada , Camperdown, Australia , Chertsey, United Kingdom , Daw Park, Australia , Eindhoven, Netherlands , Gdansk, Poland , Glebe, Australia , Hamilton, Canada and 12 more locations